The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy
This case highlights the potential of epcoritamab combined with debulking therapy for treating CAR-T-refractory CD19-negative DLBCL. This is the first validated case in Japan showing that epcoritamab is a viable and safe treatment option for post-CAR-T relapse, addressing a critical unmet need in the current therapeutic landscape.
Authors
- Yuichiro Semba (ORCID: https://orcid.org/0000-0001-8576-3530)
- Kyohei Mori
- Ken Takigawa
- Ryoukichi Ikeda (ORCID: https://orcid.org/0000-0003-0076-6092)
- Kohta Miyawaki (ORCID: https://orcid.org/0000-0003-0526-4016)
- Ikuo Kikuchi
- Takahiro Maeda (ORCID: https://orcid.org/0000-0003-4530-6460)
- Fumiaki Jinnouchi (ORCID: https://orcid.org/0000-0003-1031-1980)
- Takuji Yamauchi (ORCID: https://orcid.org/0000-0002-6238-3145)
- Koji Kato (ORCID: https://orcid.org/0000-0002-7397-1575)
- Soichiro Shiraishi
- Kiyoshi Yamashita
- Yasuo Mori (ORCID: https://orcid.org/0000-0001-6425-1720)
- Teppei Sakoda (ORCID: https://orcid.org/0000-0002-7521-0366)
- Masatoshi Shimo
- Koichi Mashiba
- Kennosuke Karube (ORCID: https://orcid.org/0000-0002-1205-858X)
- Minoru Otsu
- Takashi Nakaike
- Sawako Matsuzaki
- Koichi Akashi (ORCID: https://orcid.org/0000-0001-7763-5723)
- Takashi Shimakawa
- K Ohshima
- Kousuke Marutsuka
- Noriaki Kawano
Institutions
- Kurume University (JP)
- Kyushu University (JP)
- Kyushu University Hospital (JP)
- Miyazaki Prefectural Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- BLOOD CELL THERAPY / The official journal of APBMT
- Published
- 2025-01-01
- DOI
- https://doi.org/10.31547/bct-2024-037
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00